China Ulcerative Colitis Market

China Ulcerative Colitis Market Analysis

The China Ulcerative Colitis Market size is estimated at USD 253.53 million in 2025, and is expected to reach USD 357.98 million by 2030, at a CAGR of 7.14% during the forecast period (2025-2030).

The factors driving the market growth include the rising burden of ulcerative colitis and rising research and development for developing novel therapies, among others.

The rising burden of ulcerative colitis (UC) in China is anticipated to drive market growth in the country due to the increased adoption of UC therapeutics. For instance, according to the study published in Hans Publishers Inc. in April 2024, over the next five years, the prevalence of ulcerative colitis disease in China is projected to grow rapidly. Research suggests that the number of new UC cases in China will stabilize between 2030 and 2034. While China has increasingly prioritized UC in recent years, with significant improvements in diagnosis and treatment and continuous innovation in drugs and therapies, patient remission rates remain limited to 30%–60%. This is attributed to the disease's non-specific characteristics, variations among patients, the interaction of multiple symptoms, and the occurrence of complications.

Rising advancements in ulcerative colitis treatment, such as advanced diagnostics and treatment modalities in China, are anticipated to drive the market's growth. For instance, according to a study published in the Chinese Journal of Inflammatory Bowel Diseases in January 2024, China has achieved notable progress in basic and clinical research related to ulcerative colitis. Additionally, advanced diagnostic techniques, treatment methodologies, and new therapeutic drugs are being increasingly adopted in clinical settings in China. Therefore, such advancements are anticipated to increase the development of innovative drugs for ulcerative colitis in the country, boosting market growth.

Furthermore, the rising research on the drug discovery for ulcerative colitis in China is anticipated to drive market growth over the forecast period. For instance, according to the study published in the Chinese Journal of Inflammatory Bowel Diseases in April 2023, there is a huge research and development of new oral small molecule drugs for inflammatory bowel diseases such as ulcerative colitis and the oral small molecule drugs have better safety and efficacy. Therefore, the rising research and development for ulcerative colitis therapeutics benefit patients from a wider choice of treatment drugs, thereby anticipated to drive the market growth.

Therefore, the rising burden on ulcerative colitis, the rising research and development and increasing initiatives from the key market players are the factors anticipated to increase the market growth over the forecast period. However, high levels of unmet clinical need in ulcerative colitis and side-effects of medications are the factors anticipated to hamper the market growth.

China Ulcerative Colitis Market Trends

Immunomodulators Segment is Anticipated to Show Significant Growth Over the Forecast Period.

The pathogenesis of ulcerative colitis has led to the development of new treatment options and has progressively resulted in more frequent use of immunomodulators. The factors driving the segment growth include the rising adoption of immunomodulators and rising initiatives from the key market players.

The rising advancements in novel targeted therapeutic agents, such as immunomodulators for treating ulcerative colitis, are anticipated to drive segment growth. For instance, according to a study published in the Chinese Journal of Pediatric Medicine in April 2024, advancements in the understanding of the immunopathology of inflammatory bowel disease have led to the development of targeted therapeutics, such as immunomodulators, offering significant benefits to patients. These treatments focus on key pathways, including pro-inflammatory mechanisms such as the interleukin (IL)-12/IL-23 axis, IL-6, the tumor necrosis factor-α (TNF-α) pathway, and Janus kinase (JAK). These innovations represent a pivotal shift in the treatment landscape for ulcerative colitis with the increased inclination towards immunomodulatory drugs, boosting the segment growth.

Furthermore, rising initiatives such as partnerships among key market players are anticipated to drive segment growth over the forecast period. For instance, in May 2024, Genentech, a subsidiary of Roche, received approval from China's Center for Drug Evaluation (CDE) for its vixarelimab injection. The drug is slated for clinical trials aimed at treating ulcerative colitis. Therefore, the evaluation of new immunomodulation drugs in Chinese market is anticipated to expidate the development of novel immunomodulatory drugs over the forecast period, thereby anticipated to escalate the segment demand.

Therefore, the rising demand for immunomodulators along with the rising initiatives from the key market players are the factors anticipated to drive the segment growth.

Hospital Pharmacies Segment is Expected to Show Significant Share over the Forecast Period.

The hospital pharmacies segment is anticipated to show a significant share in the China ulcerative colitis market due to the rising number of hospitals, rising hospital admission, and treatments among others.

The rising number of hospitals in China will drive market growth over the forecast period due to the rise in hospital pharmacies. For instance, according to the Government of China statistics published in August 2024, the total number of medical and health institutions across the country reached 1,070,785 by the end of 2023. This figure comprised 38,355 hospitals, 1,016,238 primary medical and health institutions, and 12,121 specialized public health institutions. The number of hospitals grew by 1,379, while primary medical and health institutions expanded by 36,470 compared to the previous year.

Furthermore, the huge number of hospital pharmacies in China is anticipated to increase the sales of ulcerative colitis therapeutics in the country, thereby driving market growth. For instance, according to the report published by Toubao Information Technology in 2023, the public hospital drug sales channel in China accounted for 63.5% in China. Such a high percentage of hospital pharmacies is anticipated to propel the segment growth due to increased adoption of ulcerative colitis drugs from hospital pharmacies.

Therefore, owing to the high number of hospital pharmacies and rising number of hospitals, the segment is anticipated to show a significant growth over the foreacast period.

China Ulcerative Colitis Industry Overview

The China ulcerative colitis market is semi-consolidated, with major players holding a significant share. The factors owing to the competition include the rising research and development activities, rising launch of innovative medicines, and rising partnership among key market players. Some of the players operating in the market include AbbVie Inc, Celltrion Healthcare, GlaxoSmithKline Plc , Hoffmann-La Roche AG, and Pfizer Inc among others.

China Ulcerative Colitis Market Leaders

China Ulcerative Colitis Market News

• July 2024: Everest Medicines, a biopharmaceutical company specializing in the research, development, manufacturing, and commercialization of innovative therapies, announced today that VELSIPITY (etrasimod) has delivered positive top-line results in the maintenance phase of a multicenter Phase III clinical trial conducted in Asia. This trial targets treating moderately to severely active ulcerative colitis (UC). Etrasimod, an advanced oral therapy administered once daily, is convenient, effective, and demonstrates a strong safety profile.
• June 2024: Asieris Pharmaceuticals disclosed that the latest research findings on its proprietary oral drug APL-1401 for active ulcerative colitis have been published in Cellular Immunology. The Phase Ib clinical trial application for APL-1401, targeting moderate to severe active UC, has received approval from both the United States Food and Drug Administration and the National Medical Products Administration. This trial, designed to assess the drug's safety, tolerability, pharmacokinetics, and preliminary efficacy, is being conducted simultaneously at 12 centers in China and the United States.